High-Flying Novo Nordisk Dips On Disappointing Data for Weight-Loss Pill
Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people lose weight in the mid-stage study,
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...
Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...
9don MSN
An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early ...
Novo Nordisk (NVO) stock is falling Friday morning after the pharmaceutical giant shared that additional weight loss tied to ...
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
Novo Nordisk presented data on its next-generation weight-loss candidate, amycretin, which showed a significant 13% weight ...
Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback